Originally posted by AllSeq
View Post
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
-
Comment
-
Originally posted by GenoMax View PostI thought the only default option one had was to deny existence/all knowledge of the "entity" that was subject of a NDA. I was surprised at your admission in that context.
I'm from New Jersey...we bury NDA's in the Meadowlands or under Giants Stadium.
Comment
-
The embargo has been lifted so we can finally talk about the new Ion S5 – it’s basically a streamlined combination of the PGM and Proton made as easy to use as possible for ‘novice users’. See our blog post for more details and then tell us what you think: A useful addition to the NGS market? Too little too late?
Comment
-
Originally posted by GW_OK View PostDoes anyone know reagent costs? All I'm seeing discussed is equipment price.
Comment
-
As far as I can tell, costs are almost the same when comparing PGM-318 vs S5-520 and Proton PI vs S5-540. Correct?
So really what is missing with the S5 is the low-output low-cost option of the PGM-314 and -316. Not sure if that is such a smart idea, since there are labs around that want to run a low throughput sample quickly without waiting for more samples to come in. That has been one of the big plus points for Ion IMHO, plus the extremely well working Ampliseq custom panels......
Comment
-
Originally posted by Xray1 View PostAs far as I can tell, costs are almost the same when comparing PGM-318 vs S5-520 and Proton PI vs S5-540. Correct?
So really what is missing with the S5 is the low-output low-cost option of the PGM-314 and -316. Not sure if that is such a smart idea, since there are labs around that want to run a low throughput sample quickly without waiting for more samples to come in. That has been one of the big plus points for Ion IMHO, plus the extremely well working Ampliseq custom panels......
As far as the quality of sequencing, so far, so good (maybe even a bit better than the PGM).
Comment
Latest Articles
Collapse
-
by seqadmin
During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.
Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...-
Channel: Articles
09-09-2024, 10:59 AM -
-
by seqadmin
The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...-
Channel: Articles
08-27-2024, 04:44 AM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, Today, 06:25 AM
|
0 responses
13 views
0 likes
|
Last Post
by seqadmin
Today, 06:25 AM
|
||
Started by seqadmin, Yesterday, 01:02 PM
|
0 responses
12 views
0 likes
|
Last Post
by seqadmin
Yesterday, 01:02 PM
|
||
Started by seqadmin, 09-18-2024, 06:39 AM
|
0 responses
14 views
0 likes
|
Last Post
by seqadmin
09-18-2024, 06:39 AM
|
||
Started by seqadmin, 09-11-2024, 02:44 PM
|
0 responses
14 views
0 likes
|
Last Post
by seqadmin
09-11-2024, 02:44 PM
|
Comment